trending Market Intelligence /marketintelligence/en/news-insights/trending/StCVeC4AMHAE_4DtC5X0Tg2 content esgSubNav
In This List

Approval for Astrazeneca, Merck & Co.; designation for Savara

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Approval for Astrazeneca, Merck & Co.; designation for Savara

Approvals and designations made by the U.S. Food and Drug Administration for the week ended Jan. 3.

Approvals

* AstraZeneca PLC and Merck & Co. Inc.'s Lynparza as a stand-alone maintenance therapy for BRCA-mutated pancreatic cancer that has spread but has not progressed for at least 16 weeks following first-line platinum-based chemotherapy.

SNL ImageFDA headquarters in Silver Spring, Md.
Source: AP Photo

Breakthrough therapy

* Savara Inc.'s Molgradex for autoimmune pulmonary alveolar proteinosis.